The Lyxor HLT ETF (UCITS), created in 08/2006 is listed in Euro on Euronext and reproduces the Stoxx600 Healthcare Europe index which is made up of the 55 main European stocks in the sector, It should be noted that non-eurozone stocks represent 71% of the index which is not insignificant given the potentially significant fluctuations of the £ and CHF against the Euro.
The fees of this ETF are 0.3% in the average of our selection and the AUM is approximately € 316M. The replication method is indirect (via a swap) and the distribution method is capitalized. This ETF is eligible for P.E.A.
Alternative ETFs: SYH (BNP Paribas Easy Euro), CH5 (Amundi Euro).
Index & components
The two major Swiss pharmaceutical stocks (Novartis and Roche) account for around 32% of the capitalization.
The five largest stocks are in addition to the two Swiss stocks: Glaxosmithkline, Astrazeneca and Sanofi, which account for 52% of the index.
Market capitalizations are also huge: more than CHF 200 billion for Roche and Novartis, while the following 3 are around € 100 billion; this is a very important factor of inertia and offsets the relative narrowness of the index.
We also note that the overwhelming majority of companies that make up the index are pharmaceuticals, with the exception of Essilor (Ophthalmic Lenses), Philips (Equipments) and Fresenius (Healthcare Facility), so we view HLT essentially as an ETF pharma Europe.
The pharmaceutical index is not very volatile, because of the weight of its constituents as well as because of a proven defensive profile, which is explained by the fact that the discovery of molecules and their distribution is little related to economic cycles, while that in developed countries medicines are reimbursed by mutuals or by the State. In addition, health is a growth sector whose main drivers are innovation and growing markets linked to the pathologies of the developed world (aging and diabetes), as well as new viruses and antibiotic resistance. In addition, emerging markets are an important market for the European pharmaceutical industry.
The sector is facing the increasing maturity of molecule portfolios, price pressure in some areas (eg diabetes) and state budget efforts to reduce health costs. The solution lies in the innovation and partnerships / buyouts of biotech companies that should accelerate in the coming months-because valuations have become attractive again-with the key to new molecules with high potential to boost existing portfolios.
Large tax-motivated mergers seem to have long been buried since the failure of the AstraZeneca / Pfizer operation, but the sector is also impacted by US regulatory uncertainties and regular pressure to lower drug prices. The ETF HLT remained stable in 2018 while the Stoxx600NR fell sharply (-10.7%) and currently shows a performance of + 11% since the beginning of the year, slightly below thebenchmark. The performance of the index is driven by its defensive status as fears over the global cycle are exacerbated by growing tensions between China and the US.
